ProthenaProthena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease.
I don't know how you can compare our antibody with Prothenas, they remove plaque and monomers and that has been proven to be the wrong course.